{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:05:47Z","timestamp":1771257947382,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00417-023-06329-1","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T06:02:19Z","timestamp":1702015339000},"page":"1161-1167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2\u00a0years: the REBA extension study"],"prefix":"10.1007","volume":"262","author":[{"given":"Alper","family":"Bilgic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc March","family":"de Ribot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Vasavada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus Hernan","family":"Gonzalez-Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Sudhalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somnath","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"14","key":"6329_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419\u201331","journal-title":"N Engl J Med"},{"issue":"1","key":"6329_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57-65.e5","journal-title":"Ophthalmology"},{"issue":"9","key":"6329_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","volume":"116","author":"DS Boyer","year":"2009","unstructured":"Boyer DS, Heier JS, Brown DM et al (2009) A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116(9):1731\u20131739","journal-title":"Ophthalmology"},{"issue":"5","key":"6329_CR4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S et al (2015) Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159(5):915\u201324.e2","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"6329_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"119","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S et al (2012) HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119(6):1175\u20131183","journal-title":"Ophthalmology"},{"issue":"3","key":"6329_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/bjo.2010.179499","volume":"95","author":"B Gupta","year":"2011","unstructured":"Gupta B, Adewoyin T, Patel SK, Sivaprasad S (2011) Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol 95(3):386\u2013390","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"6329_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43-58.e1","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"6329_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143(4):566\u2013583","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"6329_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","volume":"118","author":"U Schmidt-Erfurth","year":"2011","unstructured":"Schmidt-Erfurth U, Eldem B, Guymer R, EXCITE Study Group et al (2011) EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118(5):831\u20139 (dosage reduction)","journal-title":"Ophthalmology"},{"issue":"9","key":"6329_CR10","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1097\/IAE.0000000000003106","volume":"41","author":"A Bilgic","year":"2021","unstructured":"Bilgic A, Kodjikian L, Mathis T et al (2021) Single injection response to anti-vascular endothelial growth factor agents in patients with wet age related macular degeneration: incidence and characteristics. Retina 41(9):1901\u20131910","journal-title":"Retina"},{"issue":"1","key":"6329_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Singh RP, Koh A et al (2020) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89\u201399","journal-title":"Ophthalmology"},{"issue":"20","key":"6329_CR12","first-page":"30400","volume":"S2468\u20136530","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Bodaghi B, Singer M et al (2020) Expert opinion on management of intraocular inflammation, retinal vasculitis, and\/or vascular occlusion after brolucizumab treatment. Ophthalmol Retina S2468\u20136530(20):30400","journal-title":"Ophthalmol Retina"},{"issue":"20","key":"6329_CR13","first-page":"31075","volume":"S0161\u20136420","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ et al (2020) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology S0161\u20136420(20):31075\u201331077","journal-title":"Ophthalmology"},{"key":"6329_CR14","unstructured":"https:\/\/www.brolucizumab.info. Information on brolucizumab related adverse events. Accessed 15 September 2023"},{"issue":"13","key":"6329_CR15","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/jcm10132758","volume":"10","author":"A Bilgic","year":"2021","unstructured":"Bilgic A, Kodjikian L, March de Ribot F et al (2021) Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med 10(13):2758","journal-title":"J Clin Med"},{"issue":"5","key":"6329_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127(5):616\u2013636","journal-title":"Ophthalmology"},{"issue":"5","key":"6329_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/eye.2014.64","volume":"28","author":"C Ehlken","year":"2014","unstructured":"Ehlken C, Jungmann S, B\u00f6hringer D et al (2014) Switch of anti-VEGF agents is an option for non-responders in the treatment of AMD. Eye 28(5):538\u2013545","journal-title":"Eye"},{"issue":"18","key":"6329_CR18","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/jcm10184153","volume":"10","author":"A Bilgic","year":"2021","unstructured":"Bilgic A, Kodjikian L, Srivastava S et al (2021) Initial pro re nata brolucizumab for exudative AMD: the PROBE study. J Clin Med 10(18):4153","journal-title":"J Clin Med"},{"issue":"4","key":"6329_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.4103\/ijo.IJO_2513_21","volume":"70","author":"D Chakraborty","year":"2022","unstructured":"Chakraborty D, Maiti A, Sengupta S, Mondal S, Nandi K, Chakraborty S (2022) Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes - a multicenter retrospective study. Indian J Ophthalmol 70(4):1295\u20131299","journal-title":"Indian J Ophthalmol"},{"issue":"10","key":"6329_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","volume":"127","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L et al (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 127(10):1345\u20131359","journal-title":"Ophthalmology"},{"issue":"1","key":"6329_CR21","first-page":"129","volume":"34","author":"I Puxeddu","year":"2016","unstructured":"Puxeddu I, Caltran E, Rocchi V et al (2016) Hypersensitivity reactions during treatment with biological agents. Clin Exp Rheumatol 34(1):129\u2013132","journal-title":"Clin Exp Rheumatol"},{"key":"6329_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/CIA.S135364","volume":"12","author":"SA Kabanarou","year":"2017","unstructured":"Kabanarou SA, Xirou T, Mangouritsas G et al (2017) Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration. Clin Interv Aging 12:911\u2013915","journal-title":"Clin Interv Aging"},{"issue":"2","key":"6329_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/ICB.0b013e3181cd1da1","volume":"5","author":"M Miura","year":"2011","unstructured":"Miura M, Iwasaki T, Goto H (2011) Macular hole formation after intravitreal bevacizumab administration in a patient with myopic choroidal neovascularization. Retin Cases Brief Rep 5(2):149\u20135220","journal-title":"Retin Cases Brief Rep"},{"issue":"6","key":"6329_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41433-022-02092-5","volume":"37","author":"DR Sally","year":"2023","unstructured":"Sally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS (2023) Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 37(6):1242\u20131248","journal-title":"Eye (Lond)."},{"issue":"6","key":"6329_CR25","first-page":"743","volume":"27","author":"JS Yu","year":"2021","unstructured":"Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC (2021) Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm 27(6):743\u2013752","journal-title":"J Manag Care Spec Pharm"},{"key":"6329_CR26","doi-asserted-by":"publisher","unstructured":"Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, Chin AT, Boyer D, Dayani P, Arepalli S, Kaiser P (2021) Brolucizumab-early real-world experience: BREW study. Eye (Lond) 35(4):1045-1047. Epub 2020 Jul 24. Erratum in: Eye (Lond). 2020 Dec 15.\u00a0https:\/\/doi.org\/10.1038\/s41433-020-1111-x","DOI":"10.1038\/s41433-020-1111-x"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-023-06329-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-023-06329-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T08:07:25Z","timestamp":1712218045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-023-06329-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["6329"],"URL":"https:\/\/doi.org\/10.1007\/s00417-023-06329-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the tenets of the Declaration of Helsinski and was approved by an international review board (Ethics Committee of the French Society of Ophthalmology, IRB 00008855 Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Ophtalmologie IRB#1). Patients gave their informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Laurent Kodjikian is consultant for Allergan\/Abbvie, Bayer, Horus, Novartis, Roche, and Th\u00e9a. Martin S Spitzer is consultant for Apellis, Abbvie, Bayer, Neurogene, and Roche. Thibaud Mathis is consultant for Allergan\/Abbvie, Bayer, GSK, Horus, and Novartis. Other authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}